Ignite Creation Date:
2025-12-25 @ 3:20 AM
Ignite Modification Date:
2026-01-01 @ 4:21 AM
Study NCT ID:
NCT00840905
Status:
COMPLETED
Last Update Posted:
2012-11-07
First Post:
2009-02-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Examine the Human Papillomavirus Types Exposure in Women From Southern Africa and Brasil
Sponsor:
Cynthia S Firnhaber
Organization:
Study Overview
Official Title:
A Pilot Observational Study to Determine the Prevalence of HPV Serology in HIV Seropositive Women From Subsaharan Africa and Brasil
Status:
COMPLETED
Status Verified Date:
2012-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study to determine what Human Papillomavirus HIV seropositive women in Botswana, South Africa and Brasil have been exposed to during their life. The Human Papillomavirus causes cervical cancer. Different types are more likely to lead to cancer than other types. A vaccine has been made to fight infection against HPV 16 and 18 which has been shown to cause cervical cancer in America and Europe. What HPV type cause cancer in other countries is not as well studied.
Hypothesis HPV serology will demonstrate that exposure to each HPV type in Gardisil (6,11,16,18) will be \<50% in HIV seropositive women in resource limited countries.
Hypothesis HPV serology will demonstrate that exposure to each HPV type in Gardisil (6,11,16,18) will be \<50% in HIV seropositive women in resource limited countries.
Detailed Description:
Plasma from HIV seropositive women will be taken and sent to MERCK in the USA to evaluate what the antibody titers of HPV 6,11,16 and 18. .
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: